Abstract
Web-based survey and anecdotal evidence suggest that many people infected with covid-19 go on to develop long covid (symptoms persisting for more than 12 weeks) despite mild initial disease. There is particular concern that this epidemic is unfolding in the younger population where vaccination rates are low. The Covid Infection Survey (CIS) has recently published estimates of the proportion of people with long covid whose daily activities are affected a little or a lot.
This paper focuses on the population aged under 35 years and uses the term ‘disabling long covid’ to describe those with symptoms lasting more than 12 weeks and daily activities limited a lot. By applying the CIS estimates to confirmed infections, with age breakdown from mid-2020 population estimates, this paper reports a first estimate of the cases of disabling long covid seeded from confirmed covid-19 infections to July 31st 2021.
Results suggest there will approximately 39,000 cases of disabling long covid in those aged under 35 seeded by Covid-19 infections confirmed to July 31st. There is a need for rapid action to prevent Covid-19 infection in the younger population and support those struggling with Long Covid-related disability.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A secondary analysis from public data
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The secondary analysis reported here used only publicly available data
